Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Immunologic tumor diagnosis].

B Schmolke1

  • 1Immunologischen Laboratorien, Berlin.

Zeitschrift Fur Lymphologie. Journal of Lymphology
|December 1, 1990
PubMed
Summary
This summary is machine-generated.

Tumour markers, substances from cancer cells, aid in prognosis and monitoring after surgery. However, current markers are not effective for early cancer detection.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Inhibition of leukotriene B4-induced CD11B/CD18 (Mac-1) expression by BIIL 284, a new long acting LTB4 receptor antagonist, in patients with rheumatoid arthritis.

Annals of the rheumatic diseases·2004
Same author

[Laboratory diagnosis of osteoporosis].

Der Orthopade·2001
Same author

[New immunoassay for oncology. Cancer test in a combination pack? Interview by Dipl.-Bioch. Petra Eiden].

MMW Fortschritte der Medizin·2001
Same author

[Colleagues, return the certification and work only for cash!. Interview by Werner Loosen].

MMW Fortschritte der Medizin·2000
Same author

Laminin fragment P1 in the sera of patients with pulmonary sarcoidosis.

Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG·1996
Same author

[Abdominal variant of benign symmetrical Launois-Bensaude lipomatosis].

Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·1995

Area of Science:

  • Biochemistry
  • Immunology
  • Oncology

Context:

  • Tumour markers are endogenous or stimulated substances released by malignant growths into body fluids.
  • Detection utilizes sensitive immunological methods, including monoclonal antibodies for enhanced diagnostics.

Purpose:

  • To outline the role and limitations of tumour markers in cancer diagnostics and patient management.
  • To highlight the current applications and future potential of tumour marker technology.

Summary:

  • Tumour markers encompass oncofetal antigens, hormones, enzymes, and proteins originating from or stimulated by cancer.
  • Quantitative detection in body fluids is achievable via immunological assays.
  • Monoclonal antibody-based determination has improved diagnostic accuracy.

Related Experiment Videos

Impact:

  • Tumour markers are crucial for preoperative prognostication and postoperative patient follow-up.
  • Despite advancements, existing tumour markers are insufficient for the early detection of malignancies.
  • Further research is needed to develop markers for early cancer recognition.